Use of hydroxychloroquine for pre-exposure prophylaxis in COVID 19: debate and suggested future course

References

• Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020;382:2081–2090.
   PubMed Web of Science ®Google Scholar
• Van Vinh Chau N, Lam VT, Dung NT, et al. The Natural History and Transmission Potential of Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clin Infect Dis [Internet]. [cited 2020 Jun 11]. Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa711/5851471.
   Google Scholar
• Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.
   Google Scholar
• National Taskforce for COVID-19. Revised advisory on the use of Hydroxychloroquine (HCQ) as prophylaxis for SARS-CoV-2 infection (in supersession of previous advisory dated 23rd March, 2020) [Internet]. Indian Coun Med Res; 2020 [cited 2020 Jun 11]. Available from:https://www.icmr.gov.in/pdf/covid/techdoc/V5_Revised_advisory_on_the_use_of_HCQ_SARS_CoV2_infection.pdf.
   Google Scholar
• Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. Internet]. 2020 [cited 2020 Jun 15]; 71:732–739. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa237/5801998.Available from:
   Web of Science ®Google Scholar
• Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.
   PubMed Web of Science ®Google Scholar
• Fantini J, Di Scala C, Chahinian H, et al. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 2020;55:105960.
   PubMed Web of Science ®Google Scholar
• Chatterjee P, Anand T, Singh K, et al. Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19. Indian J Med Res. 2020;151:459.
   Web of Science ®Google Scholar
• Tilangi P, Desai D, Khan A, et al. Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach. Lancet Infect Dis. Internet]. 2020 [cited 2020 Jun 25]; Available from: https://linkinghub.elsevier.com/retrieve/pii/S1473309920304308.
   PubMed Web of Science ®Google Scholar
• Dowall SD, Bosworth A, Watson R, et al. Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. J Gen Virol. 2015;96:3484–3492.
   PubMed Web of Science ®Google Scholar
• Paton NI, Lee L, Xu Y, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis. 2011;11:677–683.
   PubMed Web of Science ®Google Scholar
• Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. 2020;79:859–866.
   PubMed Web of Science ®Google Scholar
• Sbidian E, Penso L, Herlemont P, et al. Comment on ‘Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19ʹ by Konig et al. Long-term exposure to hydroxychloroquine or chloroquine and the risk of hospitalisation with COVID-19: a nationwide, observational cohort study in 54 873 exposed individuals and 155 689 matched unexposed individuals in France. Ann Rheum Dis. [Published Online first]. 28 Aug 2020;annrheumdis-2020-218647.
   PubMedGoogle Scholar
• S Mm L, Nicol MR, Bangdiwala AS, et al. Safety of Hydroxychloroquine among outpatient clinical trial participants for COVID-19 [Internet]. Infect Dis (except HIV/AIDS); 2020 [cited 2020 Sep 3]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.07.16.20155531
   Google Scholar
• Farré N, Mojón D, Llagostera M, et al. Prolonged QT interval in SARS-CoV-2 infection: prevalence and prognosis. J Clin Med. 2020;9:2712.
   Web of Science ®Google Scholar
• Chorin E, Wadhwani L, Magnani S, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm. 2020;17:1425–1433.
   PubMed Web of Science ®Google Scholar
• Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. Internet]. 2020 [cited 2020 Jun 9]; 5:1036. Available from: https://jamanetwork.com/journals/jamacardiology/fullarticle/2765631
   PubMed Web of Science ®Google Scholar
• Bessière F, Roccia H, Delinière A, et al. Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiol. Internet]. 2020 [cited 2020 Sep 8]; 5:1067. Available from: https://jamanetwork.com/journals/jamacardiology/fullarticle/2765633
   PubMed Web of Science ®Google Scholar
• Ramireddy A, Chugh H, Reinier K, et al. Experience with hydroxychloroquine and azithromycin in the coronavirus disease 2019 pandemic: implications for QT interval monitoring Internet]. 2020 [cited 2020 Sep 8];9. J Am Heart Assoc. Available from: https://www.ahajournals.org/doi/10.1161/JAHA.120.017144
   PubMed Web of Science ®Google Scholar
• Saleh M, Gabriels J, Chang D, et al. Effect of chloroquine, hydroxychloroquine, and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection Internet]. 2020 [cited 2020 Jun 26];13. Circ Arrhythm Electrophysiol. Available from: https://www.ahajournals.org/doi/10.1161/CIRCEP.120.008662
   PubMed Web of Science ®Google Scholar
• Pharmacovigilance Memorandum. Reference ID: 4610984. Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology; 2020.
   Google Scholar
• Nagaraja BS, Ramesh KN, Dhar D, et al. HyPE study: hydroxychloroquine prophylaxis-related adverse events’ analysis among healthcare workers during COVID-19 pandemic: a rising public health concern. J Public Health. Internet]. 2020 [cited 2020 Jun 14]; 42(3):493–503. Available from: https://academic.oup.com/jpubhealth/advance-article/doi/10.1093/pubmed/fdaa074/5850534
   Google Scholar
• Mazzitelli M, Davoli C, Scaglione V, et al. Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19. Travel Med Infect Dis. 2020;37:101826.
   PubMed Web of Science ®Google Scholar
• Owens B. Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology. Lancet Rheumatol. 2020;2:e257.
   PubMedGoogle Scholar